Log In
Print this Print this

Oral anti-CD3 mAb (TRX-318)

  Manage Alerts
Collapse Summary General Information
Company Therapix Biosciences Ltd.
DescriptionOral anti-CD3 mAb
Molecular Target CD3
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today